Welcome to our dedicated page for Eli Lilly & Co. news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Eli Lilly & Co. stock.
Eli Lilly and Company (NYSE: LLY), founded in 1876 by Colonel Eli Lilly, is a global leader in the pharmaceutical industry, headquartered in Indianapolis, Indiana. With operations in 18 countries and products sold in approximately 125 countries, Eli Lilly is dedicated to pioneering life-changing discoveries through innovative drug development. The company focuses on several therapeutic areas including neuroscience, cardiometabolic, cancer, and immunology.
Key products in Eli Lilly’s portfolio include Verzenio for cancer treatment; Jardiance, Trulicity, Humalog, Humulin, Mounjaro, and Zepbound for diabetes management; and Taltz and Olumiant for immunology. The company's recent financial performance has been robust, with Q1 2024 revenues increasing by 26% year-over-year to $8.77 billion, driven by strong sales of Mounjaro and Zepbound.
Eli Lilly continues to expand its manufacturing capabilities to meet growing demand, recently investing $5.3 billion in its Lebanon, Indiana site. This commitment supports the production of key therapies, particularly for chronic diseases like obesity and type 2 diabetes. The company’s innovative endeavors include the development of new treatments such as the once-weekly insulin efsitora alfa, which showed promising results in phase 3 trials for type 2 diabetes.
The company is also advancing its pipeline of oncology treatments with presentations of data on products like Verzenio, Retevmo, olomorasib, and imlunestrant at major medical conferences. Furthermore, Eli Lilly announced a major leadership change with Melissa Seymour joining as Executive Vice President of Global Quality, ensuring the sustained excellence of their product offerings.
Eli Lilly’s commitment to addressing significant health challenges is evident in its diverse product pipeline and ongoing clinical trials. The company remains focused on improving patient outcomes globally by harnessing advancements in biotechnology, chemistry, and genetic medicine.
Eli Lilly announced positive results from its Phase 3 trials for lebrikizumab, an IL-13 inhibitor for atopic dermatitis (AD). Responders at Week 16 maintained skin clearance and itch relief after a year of treatment, with similar efficacy between every four weeks and every two weeks dosing. Regulatory submissions to the U.S. FDA and EU EMA are planned for this year. Notably, the trials showed a stable safety profile, with most adverse events being mild to moderate.
Eli Lilly and Company (NYSE: LLY) announced its participation in the 2022 European Society for Medical Oncology (ESMO) Congress, scheduled for September 9-13, 2022. The company will present key data on its drugs Verzenio® (abemaciclib) and Retevmo® (selpercatinib). Highlights include interim overall survival results from the Phase 3 MONARCH 3 study for Verzenio in advanced breast cancer, and long-term follow-up data for Retevmo in medullary thyroid cancer and non-small cell lung cancer. These presentations aim to advance understanding and treatment options in oncology.
Eli Lilly (NYSE: LLY) will attend the Morgan Stanley 20th Annual Global Healthcare Conference on Sept. 13, 2022. Anat Ashkenazi, the company's CFO, will take part in a fireside chat at 11:10 a.m. Eastern time.
A live audio webcast of the event will be accessible on Lilly's Investor website, with a replay available for 90 days. Lilly has a legacy of nearly 150 years in pioneering medicines that improve lives, helping over 47 million people globally, and is focused on addressing major health challenges.
Eli Lilly and Company (NYSE: LLY) will participate in Citi's 17th Annual BioPharma Conference on September 7, 2022. Daniel Skovronsky, M.D., Ph.D., the company's chief scientific and medical officer, will engage in a fireside chat at 3:30 p.m. ET. A live audio webcast will be accessible via Lilly's Investor website, with a replay available for approximately 90 days.
For over 150 years, Lilly has focused on creating innovative medicines, helping over 47 million people globally. Their ongoing research aims to address critical health challenges, including diabetes, obesity, and Alzheimer's disease.
Eli Lilly and Company (NYSE: LLY) announces key leadership changes as Stephen Fry, Senior Vice President of Human Resources and Diversity, will retire at the end of 2022 after over 35 years with the company. Eric Dozier, currently Vice President and Chief Commercial Officer for Loxo@Lilly, is promoted to succeed Fry and will focus on enhancing Lilly's human resources and diversity strategy. Winselow Tucker will join as Senior Vice President and Chief Commercial Officer for Loxo@Lilly, bringing extensive experience from Bristol Myers Squibb, Novartis, and Celgene to drive growth in the oncology and hematology sectors.
Eli Lilly and Company (LLY) announced the launch of a new citrate-free formulation of Taltz (ixekizumab) injection, approved by the FDA in May 2022. This formulation aims to reduce injection site pain by 86% compared to the original. Taltz is prescribed for moderate to severe plaque psoriasis and other autoimmune conditions. Over 130,000 patients have been treated with Taltz in the U.S. since its approval in 2016. The new formulation has shown consistent safety profiles, and existing patients will not require new prescriptions during the transition period.
Eli Lilly and Company (NYSE: LLY) has rescheduled its second-quarter 2022 financial results investor conference call to 10 a.m. Eastern time due to technical difficulties. Investors and the public can access a live webcast through Lilly's website, with a replay available afterward. The company emphasizes its commitment to advancing healthcare solutions and improving patient access to medicines globally.
Eli Lilly and Company (LLY) reported Q2 2022 revenue of $6.49 billion, a 4% decline year-over-year, primarily due to lower realized prices and Alimta's generic competition. Excluding these factors, core revenue grew 6%. Key growth products, including Trulicity and Verzenio, surged 20%, comprising 67% of total revenue. EPS fell 31% to $1.05 (reported) and 32% to $1.25 (non-GAAP). The company updated its 2022 EPS guidance to $6.96-$7.11 (reported) and $7.90-$8.05 (non-GAAP). Notable advancements included the U.S. launch of Mounjaro and FDA approvals for donanemab and pirtobrutinib.
Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2022 financial results on Aug. 4, 2022, at 9 a.m. Eastern time. The company will hold a conference call to discuss its financial performance, accessible via a live webcast on Lilly's website. This event reflects Lilly's ongoing commitment to transparency with its investors and stakeholders, providing details of its business performance and future outlook.
Investors can find further information on the upcoming call and access details through Lilly's investor relations site.
Eli Lilly (NYSE: LLY) announced a modified agreement with the U.S. government to provide an additional 150,000 doses of the monoclonal antibody bebtelovimab for approximately $275 million. This supply is expected to meet the demand until late August 2022. Bebtelovimab continues to neutralize known variants, including the Omicron variants BA.2.12.1 and BA.4/BA.5. The deal is projected to generate approximately $0.08 in EPS. An option for an additional 350,000 doses exists, exercisable by September 14, 2022.
FAQ
What is the current stock price of Eli Lilly & Co. (LLY)?
What is the market cap of Eli Lilly & Co. (LLY)?
What are Eli Lilly's core business areas?
What are some of Eli Lilly's key products?
How did Eli Lilly perform financially in Q1 2024?
What recent investments has Eli Lilly made?
Who is the new Executive Vice President of Global Quality at Eli Lilly?
What are some recent clinical trial results shared by Eli Lilly?
In how many countries does Eli Lilly operate?
What is the significance of Eli Lilly's recent investment in Lebanon, Indiana?
What is the focus of Eli Lilly's ongoing research and development?
What are some common side effects of Eli Lilly's product Mounjaro?
